Brief: Oxford Cannabinoid Technologies Final Dose Of OCT461201 Administered
Sept 25 (Reuters) - Oxford Cannabinoid Technologies
Holdings PLC OCTP.L :
* OXFORD CANNABINOID TECHNOLOGIES HOLDINGS - FINAL DOSE OF
OCT461201 ADMINISTERED, DURING PHASE I CLINICAL TRIAL, WITH NO
DRUG ADVERSE EFFECTS OBSERVED.
Source text for Eikon: ID:nRSY4227Na
Further company coverage: OCTP.L
((Reuters.Briefs@thomsonreuters.com;))
Recent news on Oxford Cannabinoid Technologies Holdings
See all newsOxford Cannabinoid - Updated Shareholder Engagement
Oxford Cannabinoid - Updated Shareholder Information
Press Digest: British Business - May 9
UK's Oxford Cannabinoid Technologies slumps on delisting application
Brief: Oxford Cannabinoid Technologies Holdings Says Applied To FCA, LSE For Cancellation Of Listing Of Shares